SOMERSET, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDP, CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, announced today that Hadi Chaudhry and Stephen Snyder, CareCloud’s chief executive officer and president, will be discussing the use of generative AI in healthcare in a fireside chat on Tuesday, June 4, 2024.
The Company will be taking part in a virtual conference sponsored by Maxim Group entitled “Charting the Course: Navigating the Intersection of TMT and Business in the AI Era.” The continuous evolution of technology is paving the way for innovation across all industries, and CareCloud’s leadership will discuss how CareCloud is using generative AI to help its customers, 2,600 physician practices throughout the United States, reap the benefits of generative AI.
To register for the events or to learn more about upcoming events, please visit CareCloud's investor relations site, ir.carecloud.com/news-events/ir-calendar.
About CareCloud
CareCloud (Nasdaq: CCLD, CCLDP, CCLDO) brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve patient experience. More than 40,000 providers count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health, at www.carecloud.com.
Follow CareCloud on LinkedIn, Twitter and Facebook.
Investor Contact:
Bill Korn
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.19 |
Daily Change: | -0.05 -1.39 |
Daily Volume: | 172,080 |
Market Cap: | US$134.790M |
September 29, 2025 September 25, 2025 August 05, 2025 August 04, 2025 July 17, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load